Welcome to our dedicated page for LAVA Therapeutics N.V. SEC filings (Ticker: LVTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding LVTX’s science-heavy disclosures shouldn’t require a PhD. Every LAVA Therapeutics SEC filing packs dense clinical data on its Gammabody® bispecific T-cell engagers, R&D spending, and cash runway—details critical for judging immuno-oncology risk.
Our AI-powered platform turns those complex Form 20-F pages—and the 6-K updates that follow each trial milestone—into concise insights you can act on. Whether you search for “lava therapeutics insider trading Form 4 transactions” or “lava therapeutics quarterly earnings report 10-Q filing,” you’ll land here and find:
- Real-time Form 4 insider transactions with alerts that flag executive stock moves moments after they hit EDGAR.
- Plain-English breakdowns of annual reports—think “lava therapeutics annual report 10-K simplified”—highlighting pipeline progress, collaboration revenue, and cash burn projections.
- Side-by-side comparisons of each 6-K (8-K material events explained) so you can track dose-escalation data, FDA feedback, or new licensing deals without reading the full PDF.
Common questions are answered along the way: Where is LVTX’s proxy statement executive compensation? How do I read a lava therapeutics earnings report filing analysis? What does that shelf registration mean for dilution? Our AI extracts the numbers, footnotes, and trial endpoints that matter—saving hours while boosting confidence.
Stop searching multiple sources. Get every filing type—from S-8 share plans to F-3 offerings—plus “understanding lava therapeutics SEC documents with AI” tutorials, all updated in real time. When fresh data shapes the future of gamma-delta T-cell therapy, you’ll see it here first.
LAVA Therapeutics NV (LVTX) reported insider sales by affiliated reporting persons. On 10/08/2025, they sold 28,954 common shares at a weighted average price of $1.57 (range $1.56–$1.62). On 10/09/2025, they sold 48,169 shares at $1.56 (range $1.54–$1.59). On 10/10/2025, they sold 49,869 shares at $1.55 (range $1.53–$1.58).
Following these transactions, beneficial ownership reported as direct stood at 5,392,216, then 5,344,047, and finally 5,294,178 shares. The shares are held directly by Cooperatieve Gilde Healthcare IV U.A.; related entities Gilde Healthcare IV Management B.V. and Gilde Healthcare Holding B.V. disclaim beneficial ownership except to the extent of their pecuniary interests.
LAVA Therapeutics N.V. furnished a Form 8-K reporting a material event and attached a Press Release dated September 30, 2025 as Exhibit 99.1 and a cover page interactive data file as Exhibit 104. The filing instructs investors they can obtain SEC filings free via the SEC website or from LAVA's investor relations page and references XOMA's investor relations as an additional source. The filing identifies Fred Powell, Chief Financial Officer, as a contact. The excerpt provided does not include the press release text or details about the underlying event; it lists exhibits and distribution instructions only.
Shay Capital LLC and Shay Capital Holdings LLC reported beneficial ownership of 2,596,403 common shares of LAVA Therapeutics NV, representing 9.9% of the class as of the filing. The filers list Delaware as their place of organization and give a principal business address at 280 Park Avenue, 5th Floor West, New York, NY 10017. The filing includes a certification that the securities were not acquired or held to change or influence control of the issuer and notes an attached Joint Filing Agreement. The filing identifies the issuer's principal executive office in Utrecht, Netherlands, and provides the CUSIP N51517105.
Amendment No. 2 to a Schedule 13D reports that certain Versant-affiliated reporting persons amended prior Schedule 13D disclosures for LAVA Therapeutics N.V. (Common Shares). The filing states that on September 19, 2025 Versant Venture Capital VI, L.P. sold 2,370,533 common shares at a weighted average price of $1.4014 per share for aggregate proceeds of approximately $3,322,064.95, and Versant Vantage I, L.P. sold 532,870 common shares at the same weighted average price for proceeds of approximately $746,764.02. As of that date the reporting persons ceased to beneficially own more than 5% of the issuer's outstanding common shares. The amendment incorporates prior Schedule 13D information not changed by this filing.
Versant-affiliated entities reported insider sales of LAVA Therapeutics (LVTX) common stock on 09/19/2025. The filing shows a total of 2,903,403 shares sold in two reported transactions: 2,370,533 shares (direct) and 532,870 shares (indirect) at a weighted average price of $1.4014 per share. Following these sales, the reporting person(s) report 0 shares beneficially owned for the directly held position. The sellers are investment entities affiliated with Versant (Versant Venture Capital VI, L.P.; Versant Vantage I, L.P.; and related GP entities). The form is signed by Max Eisenberg, Chief Operating Officer, on behalf of the reporting entities.
Versant-related entities report holdings and recent sales in LAVA Therapeutics (LVTX). Versant Venture Capital VI, L.P. beneficially owns 2,370,533 common shares, representing 9.0% of the class based on 26,305,295/395 shares outstanding reported as of August 8, 2025. Versant Vantage I, L.P. beneficially owns 532,870 shares, or 2.0%. The amendment states the reporting persons reserve the right to buy or sell additional shares or take other actions with respect to their positions.
The filing discloses open-market sales executed on September 16-18, 2025. Versant VI sold 307,707, 362,806, and 366,111 shares on those dates at weighted-average prices of $1.5332, $1.4892, and $1.4418, respectively. Vantage LP sold 192,293, 226,726, and 228,791 shares on the same dates at the same respective prices. The document provides aggregate proceeds for each tranche but does not state prior ownership levels before these sales.
Versant-related entities reported multiple sales of LAVA Therapeutics (LVTX) common stock on September 16-18, 2025. The filings show a series of dispositions: on 09/16/2025 two sell transactions of 307,707 and 192,293 shares at a weighted average price of $1.5332; on 09/17/2025 two sells of 362,806 and 226,726 shares at a weighted average price of $1.4892; and on 09/18/2025 two sells of 366,111 and 228,791 shares at a weighted average price of $1.4418. Following those transactions, Versant Venture Capital VI, L.P. held 3,099,450 shares (direct) and Versant Vantage I, L.P. held 988,387 shares (indirect) before/after as specified per line entries. Footnotes state the reported prices are weighted averages from multiple transactions within disclosed ranges and describe the related fund and GP ownership relationships.
LAVA Therapeutics' board and Special Committee concluded the proposed transaction offers the highest value reasonably obtainable under current circumstances. The Purchase Agreement provides a Cash Amount of $1.16–$1.24 per share,$1.10 per share. The board determined the company lacks a viable standalone business plan after asset reviews, workforce reductions, and wind-down of clinical trials, making dissolution the most likely alternative absent a sale. Contingent Value Rights (CVRs) may provide shareholders potential additional future payments, and the board viewed the deal as offering maximum capital return, no financial risks, and high deal certainty for shareholders.
Summary
LAVA Therapeutics N.V. (Nasdaq: LVTX) convened an Extraordinary General Meeting for September 30, 2025 to seek shareholder votes on board appointments, discharge of directors and a post-offer reorganization tied to an acquisition offer from XOMA Royalty Corporation. XOMA offered $1.16 per share plus up to $0.08 additional cash per share and one contingent value right (CVR) per share, subject to the Purchase Agreement and Offer to Purchase. The Board unanimously recommends shareholders accept the Offer and vote "FOR" the EGM proposals. If conditions are met, a Downstream Merger, a loan to New Topco and cancellation of New Topco class A shares are contemplated as part of the Post-Offer Reorganization.
FAQ
What is the current stock price of LAVA Therapeutics N.V. (LVTX)?
What is the market cap of LAVA Therapeutics N.V. (LVTX)?
